Literature DB >> 2775622

Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro.

D J Back1, P Stevenson, J F Tjia.   

Abstract

Two antimycotic agents, the azole ketoconazole and the allylamine terbinafine, have been examined for their effects on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes (n = 4) in vitro. Ketoconazole caused marked inhibition of all enzyme activities with mean IC50 values (concentration producing 50% inhibition) of 17.9 microM (tolbutamide hydroxylase), 1.9 microM (ethinyloestradiol 2-hydroxylase), 2.0 microM (cyclosporin N-demethylase), 2.1 microM (cyclosporin hydroxylase) and 25 microM (ethoxycoumarin O-deethylase). At 50 microM terbinafine concentration, inhibition was less than 5% for tolbutamide and ethoxycoumarin, approximately 12% for both cyclosporin pathways and 35% for ethinyloestradiol. Terbinafine does not have the same inhibitory potential for cytochrome P-450 isozymes as ketoconazole.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775622      PMCID: PMC1379899          DOI: 10.1111/j.1365-2125.1989.tb05410.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Ketoconazole, cyclosporin metabolism, and renal transplantation.

Authors:  R M Ferguson; D E Sutherland; R L Simmons; J S Najarian
Journal:  Lancet       Date:  1982-10-16       Impact factor: 79.321

3.  Ketoconazole and cyclosporin.

Authors:  H Dieperink; J Møller
Journal:  Lancet       Date:  1982-11-27       Impact factor: 79.321

4.  An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Authors:  W F Greenlee; A Poland
Journal:  J Pharmacol Exp Ther       Date:  1978-06       Impact factor: 4.030

5.  Characterization of three highly purified cytochromes P-450 from hepatic microsomes of adult male rats.

Authors:  D E Ryan; S Iida; A W Wood; P E Thomas; C S Lieber; W Levin
Journal:  J Biol Chem       Date:  1984-01-25       Impact factor: 5.157

6.  Effect of ketoconazole on hepatic oxidative drug metabolism.

Authors:  M W Brown; A L Maldonado; C G Meredith; K V Speeg
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

7.  In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis.

Authors:  H Van den Bossche; G Willemsens; W Cools; F Cornelissen; W F Lauwers; J M van Cutsem
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

8.  Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver.

Authors:  J J Sheets; J I Mason
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

9.  The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro.

Authors:  C G Meredith; A L Maldonado; K V Speeg
Journal:  Drug Metab Dispos       Date:  1985 Mar-Apr       Impact factor: 3.922

10.  Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structure-activity relationship.

Authors:  D J Back; J F Tjia
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

View more
  19 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Cyclosporin metabolism by the gastrointestinal mucosa.

Authors:  J F Tjia; I R Webber; D J Back
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 4.  Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences.

Authors:  K T Kivistö; P J Neuvonen; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

5.  Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Authors:  D J Carlile; N Hakooz; M K Bayliss; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

6.  Cyclosporin metabolism by human gastrointestinal mucosal microsomes.

Authors:  I R Webber; W H Peters; D J Back
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

7.  Generation of oxygen free radicals during the metabolism of cyclosporine A: a cause-effect relationship with metabolism inhibition.

Authors:  F Serino; J Grevel; K L Napoli; B D Kahan; H W Strobel
Journal:  Mol Cell Biochem       Date:  1993-05-26       Impact factor: 3.396

8.  Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.

Authors:  D J Back; J F Tjia
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 9.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

10.  Short term treatment of dermatophyte onychomycosis with terbinafine.

Authors:  M J Goodfield; L Andrew; E G Evans
Journal:  BMJ       Date:  1992-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.